VRTX Technical Analysis
As of date:9/28/2022
VRTX stock price:292.41
VRTX 50 DMA:286.96
VRTX 200 DMA:260.93
VRTX MACD (200-50):-26.03
VRTX RSI:52.43
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)52.43

Also see:
VRTX Market Cap History
VRTX Shares Outstanding History

Try ChartSweeps today
Quotes delayed 20 minutes

Email EnvelopeFree VRTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Shares of BWX Now Oversold
just posted

EZA Crosses Critical Technical Indicator
just posted

Shares of EWJ Now Oversold
1 minute ago

QLD Crowded With Sellers
3 minutes ago

SFY Enters Oversold Territory
3 minutes ago

PHO Getting Very Oversold
4 minutes ago

TAN Crosses Critical Technical Indicator
4 minutes ago

STIP Crowded With Sellers
4 minutes ago

EEMV Crosses Critical Technical Indicator
5 minutes ago

Shares of QTEC Now Oversold
5 minutes ago

Karat Packaging Breaks Above 200-Day Moving Average - Bullish for KRT
17 hours, 36 minutes ago

Bullish Two Hundred Day Moving Average Cross - PGC
18 hours, 10 minutes ago

ANAB Makes Bullish Cross Above Critical Moving Average
18 hours, 11 minutes ago

Bullish Two Hundred Day Moving Average Cross - CHRD
18 hours, 12 minutes ago

Bullish Two Hundred Day Moving Average Cross - VNOM
18 hours, 12 minutes ago

More Technical Analysis News

VRTX Technical AnalysisVRTX RSI
Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

When researching a stock like Vertex Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from VRTX Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for VRTX stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Vertex Pharmaceuticals (VRTX) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

VTRS Technical Analysis
WAT Technical Analysis
XRAY Technical Analysis
ZBH Technical Analysis
ZTS Technical Analysis
A Technical Analysis
ABBV Technical Analysis
ABC Technical Analysis
ABMD Technical Analysis
ABT Technical Analysis
More Healthcare companies »


VRTX Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.